Short-term outcomes of intravitreal faricimab on refractory neovascular age-related macular degeneration patients in China

Purpose To assess the real-world clinical outcomes of faricimab in patients receiving treatment for neovascular age-related macular degeneration (nAMD). Methods This real-world prospective observational study included patients with refractory nAMD. In total, 37 patients were analyzed. All patients had previously undergone at least three consecutive intravitreal injections of other anti-vascular endothelial growth factor (anti-VEGF) agents. The primary outcomes were best-corrected visual acuity (